miércoles, 15 de mayo de 2019

There will be no surprise Humira biosimilars

The Readout
Damian Garde

There will be no surprise Humira biosimilars


The drug industry’s most lucrative single product will stay that way until 2023.

AbbVie settled a lawsuit that will extend Humira’s exclusivity for another four years, signing a deal with German drug maker Boehringer Ingelheim that will keep a biosimilar off the market. It’s not a surprising development, but it came as a disappointment to advocates who have accused AbbVie of gaming the patent system to prolong Humira’s commercial lifespan.

It also sets a firm deadline for AbbVie, which gets nearly half of its revenue from Humira. The company has been building a back-up plan in fits and starts, with some successes in auto-immune disease and more than a few disappointments in oncology.

Read more.

No hay comentarios: